StockNews.com assumed coverage on shares of CymaBay Therapeutics (NASDAQ:CBAY – Free Report) in a research report released on Saturday morning. The firm issued a sell rating on the biopharmaceutical company’s stock. Other equities analysts also recently issued research reports about the stock. Raymond James downgraded shares of CymaBay Therapeutics from an outperform rating to a […] Read this story
